REVIEW

Improving the safety of oral immunotherapy for food allergy

Vazquez-Ortiz, Marta; Turner, Paul J.

1 Imperial College London, Section of Paediatrics, London, United Kingdom; 2 Discipline of Paediatrics and Child Health, School of Medicine, University of Sydney, Sydney;

Running title: Improving the safety of OIT

Correspondence:

Dr. Paul Turner
Section of Paediatrics (Allergy & Infectious Diseases)
Imperial College London
Norfolk Place
London W2 1PG
UNITED KINGDOM

Phone: +44 (0)20 3312 7754
Fax: +44 (0)20 3312 7571
E-mail: p.turner@imperial.ac.uk

Word Count: 4463 words
Number of tables: 1
Number of figures: 2
Food allergy is a major public health problem in children, impacting upon the affected individual, their families and others charged with their care e.g. educational establishments, and the food industry. In contrast to most other paediatric diseases, there is no established cure: current management is based upon dietary avoidance and the provision of rescue medication in the event of accidental reactions, which are common. This strategy has significant limitations and impacts adversely on health-related quality of life. In the last decade, research into disease-modifying treatments for food allergy has emerged, predominantly for peanut, egg and cow’s milk. Most studies have used the oral route (oral immunotherapy, OIT), in which increasing amounts of allergen are given over weeks-months. OIT has proven effective to induce immune-modulation and “desensitization” – that is, an increase in the amount of food allergen that can be consumed, so long as regular (typically daily) doses are continued. However, its ability to induce permanent tolerance once ongoing exposure has stopped seems limited. Additionally, the short- and long-term safety of OIT is often poorly reported, raising concerns about its implementation in routine practice. Most patients experience allergic reactions and, although generally mild, severe reactions have occurred. Long term adherence is unclear, which rises concerns given the low rates of long-term tolerance induction. Current research focuses on improving current limitations, especially safety. Strategies include alternative routes (sublingual, epicutaneous), modified hypoallergenic products and adjuvants (anti-IgE, pre/probiotics). Biomarkers of safe/successful OIT are also under investigation.

Key words

Children, food allergy, oral immunotherapy, quality of life, safety.
Address for Offprints:

Dr. Paul Turner
Section of Paediatrics (Allergy & Infectious Diseases)
Imperial College London
Norfolk Place
London W2 1PG
UNITED KINGDOM
1. Introduction

Food allergy is a major public health issue throughout the world, particularly in children. There is no established treatment for use in routine clinical practice: management involves avoidance of the culprit food(s) and rescue medication in the event of accidental reactions (1). Food allergy impacts significantly on health-related quality of life (HRQoL) of both the affected individual and their families. The last decade has seen an increase in research into possible treatments for food allergy.

1.1. Impact of food allergy

Food allergy is estimated to affect up to 6% of children in Europe (2). The incidence is rising, with an 18% increase in children in the last decade in the USA (3). Hospital admissions due to anaphylaxis – the most severe manifestation of food allergy – have doubled in the UK from 1.2 per 100,000 population per annum in 1992 to 2.4 in 2012 (4), especially in children (0-14 years).

Cow’s milk, egg, peanut and tree nuts are the most common food allergens in children (2). Variations in the prevalence of allergy to different foods between countries may depend on local dietary preferences (5). Whether local consumption patterns also affects resolution of food allergies is unknown. Peanut allergy persists into adulthood in 80% of cases (6,7). In contrast, around 50% of children with cow’s milk and/or egg allergy develop tolerance within the first 5-6 years of life (8,9). Persistence of reactivity to the latter two allergens is a significant concern, because individuals frequently have more severe and complex allergic phenotype (8,9). Given the high incidence of milk and egg allergy in the general population, the absolute numbers of those with persistent disease are significant, particularly in tertiary care (10,11).

The spectrum of severity for symptoms during food allergic reactions is variable, and includes life-threatening anaphylaxis and even death (12). Cow’s milk and peanuts were the most common triggers for fatal anaphylaxis in UK children between 1992-2012 (4).

Fortunately, fatal anaphylaxis, while unpredictable, is also very uncommon, with an incidence rate of 1.81 per million person-years (95% CI 0.94-3.45) (12). However, our inability to predict those most at risk of severe reactions contributes to the widespread provision of rescue medication (such as adrenaline auto-injectors) and anxiety which impacts adversely on HRQoL to a greater degree than that reported for chronic illnesses such as diabetes or idiopathic arthritis (13,14). The most common childhood allergens – especially cow’s milk – are key
dietary constituents providing essential nutrients needed for growth and development. Dietary elimination can therefore be challenging, especially in those with multiple food allergies (15). Finally, food allergy is a major public health issue, affecting the food industry with regards to allergen risk management and mandatory allergen labelling (16). There are further cost implications, not only for affected families but also to the health system, with a doubling of direct health costs compared to non-allergic individuals (17).

1.2. Limitations of current management for food allergy

Even with appropriate dietary avoidance, accidental allergic reactions are common: up to 40% of children allergic to cow’s milk had at least one reaction every year according to one report (18). Strict avoidance in children is difficult, since the most common food allergens (cow’s milk, egg or nuts) are present in many dishes and manufactured products. Moreover, allergen labelling can be poor and confusing, increasing the potential for inadvertent allergen consumption (19). This is a particular issue with precautionary allergen labelling: a UK-based survey found 69% of cereals and 56% of confectionery items have “may contain” labelling to nuts, despite nuts not being present as an ingredient (20); such labelling is often ignored by consumers (21).

Many factors contribute to rescue medication often not being used appropriately in the community when needed. Many parents/patients—especially teenagers—do not carry their medication at all times, find it difficult to identify anaphylaxis symptoms (22,23) or to use auto-injector effectively in these stressful situations. Others are frightened because of needle-phobia or possible side effects (24). Many caregivers do not receive any formal training on anaphylaxis management from healthcare professionals. All of these issues may affect the ability of staff within education establishments (e.g. schools) to correctly identify and administer emergency medication in the event of a reaction (25). Finally, fatal cases of food-anaphylaxis have been reported, even when adrenaline was administered correctly in a timely manner (26,27).

2. Oral immunotherapy for food allergy

Given the above, there has been demand for a disease-modifying treatment for food allergy, particularly for the most common, ubiquitous and dangerous allergens in terms of fatal anaphylaxis: cow’s milk and peanut. Different strategies are under investigation, the most common approach being oral immunotherapy (OIT) with over 60 studies published in peer-
review journals. Results have been promising in terms of effectiveness and positive impact on parent-assessed HRQoL. However, significant concerns remain regarding the safety of OIT, and its ability to induce permanent tolerance. Current research focuses in improving these two key issues. The benefits and pitfalls of OIT are summarized in Table 1.

2.1. Rationale and underlying immune-modulation

OIT consists of giving increasing amounts of food allergen orally over weeks or months (“updosing phase”). Once the target dose is reached, this amount is given on a regular basis, usually daily (“maintenance phase”). This results in an allergen-specific immunomodulatory effect. A recent meta-analysis showed a reduction in skin prick test wheal size and an increase in specific IgG4 blocking antibodies following OIT to cow’s milk, egg and peanut (28), with the latter possibly being a biomarker for sustained unresponsiveness (29). A trend towards a reduction in specific IgE levels was also detected. The underlying immune mechanisms are not fully understood. Exposure to low allergen doses seem to promote inducible T regulatory cells (CD25+ FoxP3+) in gut MALT tissue, which reduces allergen-specific Th2 response through IL10 and TGFβ (30). Exposure to high allergen doses might induce allergen-specific T cell anergy or clonal deletion (31).

2.2. Effectiveness

OIT is effective in increasing the amount (or threshold) of allergen food-allergic individuals are able to eat without experiencing an allergic reaction, an effect termed desensitization. A meta-analysis by Nurmatov et al reported a significant reduction in the likelihood of reacting at a food challenge following OIT compared to controls (Risk ratio: 0.21, 95% CI: 0.12-0.38) (28). However, the ability of OIT to induce permanent or sustained tolerance – once ongoing exposure has stopped – has not, to date, been extensively evaluated. The available published data is not encouraging. In a randomized controlled trial (RCT) of OIT for egg and cow’s milk allergy in 45 young children, tolerance rates were equal (35%) in both the OIT and control group after OIT (median duration 21 months) followed by 2 months off-OIT (32). In a RCT of egg OIT, 75% (30/40) of children were desensitized at 22 months, but only 27.5% (11/40) were tolerant after stopping OIT for 4-6 weeks (33). Similar findings have been reported for peanut OIT: one uncontrolled study found that only 50% (12/24) of patients who had reached the target peanut dose (4000mg) maintain tolerance 4 weeks after stopping OIT (34).
It seems a little incongruous that for other forms of immunotherapy – such as subcutaneous immunotherapy for aeroallergens and venom, success is generally defined as tolerance (and not transient desensitization) after 3-5 years of active treatment – yet the same criteria are not applied to OIT. Further research is needed to clarify whether more a longer course of OIT would increase rates of tolerance, and whether OIT only accelerates allergy resolution in those who would have developed natural tolerance without any intervention. As it is difficult to determine for how long OIT maintenance should be stopped to prove permanent tolerance (most studies utilise a “short” off-OIT phase of 2-8 weeks), the term “sustained unresponsiveness” is preferred instead of tolerance (33).

2.3. Safety

The main limitation to OIT, and arguably the reason why the international consensus is that it is not yet ready for routine clinical practice, is the risk of allergic reactions (35). The lack of consensus in safety reporting (in contrast to other forms of allergen immunotherapy) makes it extremely difficult to appraise the frequency of reactions and thus the safety of OIT (30). Many studies focus on effectiveness and provide limited safety data. The meta-analysis by Nurmatov et al could identify data relating to systemic adverse reactions in only 5 of the 21 studies included (28). An increased risk for local reactions with OIT was reported (RR: 1.47; 95%CI: 1.11-1.95), with a similar trend for systemic reactions, especially for cow’s milk OIT (30). A previous meta-analysis assessing cow’s milk OIT reported an increased risk with OIT for adrenaline use (RR: 5.8; 95%CI: 1.6-21.9) and for all types of allergic reactions, including those potentially life-threatening such as bronchoconstriction (RR: 10; 95%CI: 2.4-41.4) or laryngospasm (RR: 12.9; 95%CI: 1.7-18.6) (36).

Although these results are self-explanatory, they do not fully show the complexity of OIT safety in terms of the frequency of reactions, their severity, evolution over time and potential relationship with cofactors or poor adherence to the OIT protocol. These essential safety data are lacking in most studies on OIT. Safety data may be provided as the proportion of doses causing reactions, rather than the proportion of patients experiencing a reaction. For example, if 5 individuals (in study of 50 patients undergoing daily OIT over 6 months) experience anaphylaxis to an OIT home dose, this at could be reported as a rate of 10% (patients) or 0.05% of doses (9125 doses administered over the 6 months). Furthermore, different classification systems are used to describe severity across studies, as are the indications to administer adrenaline. In this context, there are major limitations to compare safety outcomes across studies and identify optimal OIT regimens.
On the one hand, most studies report that OIT-related reactions are generally mild and usually tend to decrease or resolve overtime. Probably many patients may undergo successful OIT without major safety concerns (37-39). On the other hand, worrying safety data are reported in many studies: reactions occur in most patients. Studies report that 10-35% of children need to be withdrawn due to significant and/or repeated reactions; cough, wheeze or stridor (which can be regarded as potentially life-threatening) are not uncommon (40-42). Near-fatal reactions have been reported in asthmatic teenagers with poor compliance (43,44). This raises concerns about long-term safety, especially when reaching adolescence, if permanent tolerance is not achieved. Importantly, poor long-term adherence has been reported in over 60% of cases after 3-5 years on cow’s milk and peanut OIT (45,46).

2.4. Impact on quality of life, nutrition and health economics

A few open studies of OIT have shown a positive impact on children’s quality of life following successful OIT using validated questionnaires to assess HRQoL (42,47-49); however, in almost all cases, these assessments have been made in the parents and not in the children themselves undergoing OIT, despite such questionnaires being available for use in children from age 8 years. Given the potential for participation in OIT being influenced considerably by parents (rather than being up to the child), it is important that the child’s perspective and views on OIT are explored. No studies have addressed the impact of OIT on HRQoL in the longer term, or in those patients who fail OIT due to reactions. A recent study reported that parents only perceived a very limited benefit from the child undergoing egg-OIT; interestingly, the improvement in HRQoL correlated inversely with the frequency of OIT-related reactions, suggesting that if safety is compromised, quality of life does not improve (50).

No studies have, as yet, assessed whether successful OIT improves nutrition by allowing the child to re-introduce foods (such as cow’s milk) into their diet, although the impact on nutrition may be limited given that OIT is not generally performed in very young children. Studies on cost-effectiveness of OIT are also lacking at this time. OIT studies to date have focused on efficacy as the primary outcome. Whether this is the most important outcome for patients has not been evaluated. There is a need to involve patients and caregivers in defining relevant outcomes for studies on treatments for food allergy.

3. Strategies to improve the safety of immunotherapy for food allergy
Several approaches have been proposed to improve the safety of OIT. These include research on using alternative routes of exposure, modified hypoallergenic products and adjuvants for immunotherapy as well as on biomarkers of safe and successful OIT to facilitate patient selection (Figure 1).

3.1. Biomarkers of safe and successful OIT

The identification of biomarkers associated with safe (and successful) OIT might help select suitable candidates more likely to respond safely to OIT, and screen out those candidates in whom OIT may lead to unnecessary risks. Although the outcome of OIT probably depends on multiple factors, some individual characteristics might have a predictive value. In a recent study of cow’s milk-OIT, patients who were withdrawn due to significant reactions had IgE-binding to a broader diversity of peptides (especially to a-s1-casein) and at higher intensity than those children who completed OIT successfully (51). In a further study, children with frequent and severe reactions to CM-OIT had different baseline characteristics compared to those who tolerated OIT: higher CM-specific IgE levels prior to OIT, more severe reactions to low CM doses, and more severe asthma (41). The same factors were associated to early withdrawal on egg-OIT in another study (52), suggesting that OIT might be unsafe in those individuals with persistent and more severe allergy to cow’s milk and/or egg allergy. Excluding these “high risk” children may seem reasonable, but these patients have most to benefit from OIT.

3.2. Alternative routes

3.2.1. Sublingual immunotherapy (SLIT)

Several studies have used the sublingual route for food immunotherapy (peanut, cow’s milk, hazelnut, peach). This approach builds on existing evidence on the efficacy and good safety profile of SLIT for inhalant allergens (53). Effector cells (mast cells, basophils) are scarce, in the sublingual mucosa which reduces the risk of allergic reactions. Conversely, antigen presenting dendritic cells (e.g. Langerhans cells) are abundant, which may promote the induction of tolerogenic T regulatory cells (54). SLIT for food allergy mimics some of the immune changes seen with OIT. SLIT for food allergy can result in decreased titrated skin prick test and specific IgE levels, with associated allergen-specific increases in IgG4 (46,55-57). Systemic reactions are less frequent on SLIT, although they still may occur, especially if the allergen is ingested (55,58). A recent meta-analysis found SLIT was effective at inducing
desensitization (28), however, the increase in amount of food allergen that can be tolerated following SLIT is modest and lower than that achievable with OIT (55-58). Two studies have compared the efficacy of SLIT vs OIT for cow’s milk and peanut allergy, respectively. In both cases, OIT resulted in an increase in threshold up to 10 times that achieved with SLIT (55,58).

Whether this is sufficient to protect patients from accidental reactions is unclear, as the median threshold following SLIT can be relatively low: a study of peanut SLIT resulted in a median threshold for reactivity of 371 mg of peanut protein – less than 2 peanuts (59). Effectiveness appears to improve with more prolonged treatment for SLIT to cow’s milk (58), but similar studies with peanut-SLIT have provided conflicting results (59). The lower doses used for SLIT (in comparison to OIT) may contribute to its limited efficacy, but better safety profile. Whether the dose used for SLIT can be increased to try to improve efficacy without compromising safety requires investigation. Concentrating the SLIT extract to deliver higher doses did not improve efficacy in one study, although given the high dropout rate seen, these data must be interpreted with caution (46). Finally, a recent trial in peanut-allergic children suggested that pre-treatment with SLIT may improve the safety of subsequent OIT (55). This approach is deserving of further evaluation.

3.2.2. Epicutaneous immunotherapy (EPIT)

EPIT involves the application of a patch containing the food allergen to the skin. The epidermis is poorly vascularized, which might limit the potential for systemic reactions. In contrast, it contains high numbers of potent antigen presenting cells, which may allow immune-modulation and enhanced efficacy (60). Preclinical data in peanut-sensitized mice demonstrated that peanut-EPIT on intact skin decreased the clinical and allergen-specific Th2 responses, and increased local and peripheral Foxp3+ Tregs (61). Furthermore, Tregs persisted for 8 weeks after the end of EPIT, suggesting that EPIT might induce long-term tolerance (62). A pilot study in 19 children with cow’s milk allergy using EPIT for 3 months found a tendency towards an increased cumulative dose, but this was not statistically significant. No systemic reactions occurred, however local eczematous skin reactions were common (63). Larger studies with longer duration are required to evaluate the effectiveness and safety of EPIT for food allergy in humans, and phase I-II studies in peanut allergic patients are underway (Clinicaltrials.gov NCT01170286 and NCT01197053). A further possibility is that EPIT could be
combined with other routes of immunotherapy (OIT or SLIT), to improve safety and efficacy or perhaps as an alternative route of providing ongoing maintenance therapy.

3.2.3. Subcutaneous immunotherapy (SCIT)

The first trial on immunotherapy for food allergy was a RCT performed in the 1990s in 12 peanut-allergic adults using SCIT (aqueous peanut extract) for one year (64). All 6 patients on active treatment required intramuscular adrenaline for systemic reactions on more than one occasion, with anaphylaxis occurring during both the rush and maintenance phases. While SCIT resulted in an increase in threshold of reactivity at DBPCFC, the authors acknowledged that SCIT using native food allergen was unsafe. Subsequent studies have focused in the development of hypoallergenic products to improve the safety of SCIT.

3.3. Modified hypoallergenic molecules

The underlying rationale is to use products that have reduced or no ability to bind specific IgE and activate mast cells and basophils through modification of allergenic sites or epitopes. However, their ability to interact with T cells is preserved to allow immune-modulation without triggering allergic reactions. Such products can be found “naturally” in our diets or produced in the laboratory.

3.3.1. Naturally-occurring hypoallergenic foods

There is now strong evidence that baked foods containing extensively-heated cow’s milk or egg in baked foods (such as biscuits, cakes or muffins) are tolerated by approximately 70% of children with milk or egg allergy (65-67). This is a result of heat-induced protein structure modification and effects from a gluten-containing food matrix (such as the formation of protein aggregates), altering the ability of IgE to bind to mainly conformational epitopes (as opposed to linear epitopes, which are heat-resistant) and cause effector cell activation (68-70). Introducing baked foods containing egg/milk into the diet of children who are otherwise allergic to the native allergen may be a safe and simple way of accelerating natural tolerance, with both clinical and laboratory data suggesting this is the case (71,72). However, it is difficult to demonstrate that children who tolerate extensively-heated allergen outgrow their allergy due to exposure to the allergen in baked foods, or whether these individuals would outgrow their allergy through natural resolution, independent of allergen consumption. Indeed, having
IgE against specific linear peptides/epitopes is associated with clinical reactivity to baked foods, and a more persistent course of cow’s milk and egg allergy (73,74). This dilemma is difficult to test in research, due to both ethical and pragmatic reasons (a family who know their child tolerates the allergen in baked foods is unlikely to agree to strict allergen avoidance, especially when exposure may help ‘cure’ their child).

A novel approach to peanut desensitisation is currently being tested in a Phase 2/3 study (NCT02149719) using boiled peanut. This has reduced allergenicity compared to raw or roasted peanut (the latter being the usual type of peanut consumed in western countries). Boiling appears to result in the loss of key allergenic components (especially Ara h 1, 2 and 6) into the cooking water (75,76). Preliminary data suggest that boiled peanut OIT might be a safe and effective to induce desensitization in children with peanut allergy (76).

3.3.2. Engineered recombinant proteins

The introduction of point mutations into known IgE-binding epitopes of food allergens, either through chemical modification or site-directed mutagenesis, can be used to develop recombinant proteins with reduced allergenicity. Hypoallergenic mutants of peanut, fish, and apple allergens have been generated using the latter technique (77). Wood et al recently published a phase 1 trial of a rectally-administered suspension of recombinant dominant peanut allergens (Ara h 1, Ara h 2 and Ara h 3), modified by amino acid substitutions at major IgE binding epitopes and encapsulated in heat/phenol killed E. coli (EMP-123). Unfortunately, 5 out of 10 peanut-allergic adults required discontinuation due to significant allergic reactions (78). It is not clear as to whether these outcomes were affected by the route of exposure. An ongoing EU-funded study aims to develop hypoallergenic recombinant major allergens of fish (parvalbumin) and peach (lipid transfer protein) to be used as active ingredients of SCIT for food allergy (79).

3.3.3. Peptides

This approach uses overlapping peptides (protein fragments 10 to 20 amino acids long) which represent the entire sequence of the allergenic protein. These short peptides cannot cross-link two IgE molecules, but can interact with antigen presenting cells. Such approaches have been successfully used for immunotherapy to aeroallergens (80). A peptide mixture of Ara h 2, the major peanut allergen, has been tested in a mouse model of peanut allergy with
promising clinical and immunological results (81). The most relevant tolerogenic peptides need to be identified before human studies can be considered (82).

3.4. Adjuvants

3.4.1. Anti-IgE therapy

Anti-IgE appears to be a very promising therapy for IgE-mediated allergic diseases, and probably acts by two mechanisms: preventing free IgE molecule from binding to its receptors on effector cells, and through effects on effector cells including by downregulating the expression of the high-affinity IgE receptor on mast cells, and decreasing basophil histamine release (83). Evidence supporting its use in the management of food allergy is encouraging but currently limited, as reviewed elsewhere (84). In a double-blind placebo-controlled RCT in 84 peanut allergic adults, four doses of anti-IgE were given at 4 weekly intervals (given its half-life of 26 days) (85). An increase in the median threshold of reactivity from half a peanut before treatment to 9 peanuts was observed, without the use of a desensitisation protocol. However, 25% of patients did not respond, and no long-term data are described. Some studies have demonstrated the great potential of anti-IgE in combination with OIT to allow both more rapid desensitization and improved safety. Two pilot studies in children allergic to cow’s milk (n=11) and peanut (n=13) have been published, using anti-IgE from at least 8 weeks prior to OIT commencement (86,87). Around 80% of participants reached the target dose after 7-11 weeks of updosing (2000 mg cow’s milk and 4000 mg peanut protein), an effect which persisted allowing tolerance to higher doses (8000mg) at DBPCFC 8-12 weeks after stopping anti-IgE. Most patients experienced only mild allergic reactions; 2 children on peanut-OIT experienced bronchial reactions (87). During cow’s milk OIT, no bronchial, laryngeal or cardiovascular reactions occurred (although 4 patients were given adrenaline nonetheless) (86). A more recent study performed simultaneous OIT to multiple foods using anti-IgE from 8 weeks prior to 8 weeks after starting OIT (88). All children had reacted to doses <100mg protein prior to OIT, and all tolerated 4000mg for each allergen by 9 months of OIT (median time: 18 weeks).

We are also aware of anecdotal reports where anti-IgE has successfully been used as an adjuvant in desensitisation in individuals with previous multiple episodes of anaphylaxis to LTP. Although anti-IgE shows great promise in combination with OIT, more research is needed to address unclear issues before it should be considered ready for use outside the research setting. First, longer-term effectiveness of OIT once anti-IgE is stopped requires further investigation: there are case reports of IgE-facilitated OIT where clinical symptoms to the
allergen in question recurred following withdrawal of anti-IgE therapy (89). Anti-IgE does not
seem to be equally effective in all patients (and this is directly related to OIT safety); more
research is needed into understanding the reason for this, as well as into potential biomarkers
to predict individual treatment responses. Finally, the high cost of anti-IgE therapy is likely to
be prohibitive in many countries.

3.4.2. Pre/probiotics

Evidence from animal models and in vitro studies suggest that gut microbiota
modulate immune programming, promote oral tolerance, and are important inhibiting the
development of the allergic phenotype. The utility of prebiotics (non-digestible carbohydrates
that stimulate the growth and/or activity of beneficial colonic bacteria), probiotics (live
microorganisms that benefit the host) and/or symbiotics (a combination of both) in the
prevention and/or treatment of allergic diseases has been addressed in different studies (90).
Results from animal models are encouraging, but in-human data are minimal. A recent study
addressed the potential of probiotics to induce beneficial gut immune-modulation in
association with peanut-OIT (91). Tolerance rates after stopping OIT were higher than in
previous studies. However, definitive conclusions cannot be drawn, since the authors did not
include a control group receiving OIT but not probiotics. Around half of the patients
experienced significant allergic reactions to OIT.

3.4.3. Bacteria

As bacteria are potent stimulants of Th1 immune responses, modified bacterial
products are under investigation as adjuvants for allergen-specific immunotherapy. In a dog
model of food allergy, a single subcutaneous injection with a mixture of Heat-killed Listeria
monocytogenes (HKLM) and either peanut, or milk and wheat, significantly reduced
anaphylactic symptoms on oral food challenge (92). Heat/phenol killed E. coli was associated
to the above-mentioned rectal EMP-123 vaccine for peanut allergy (78).

3.4.4. Antihistamines and Leukotriene receptor antagonists

Daily antihistamines have been used during OIT updosing in several studies (37,40,93). This
is expected to reduce mild oral, skin, nasal and/or ocular symptoms related to OIT doses.
There is anecdotal evidence of the potential usefulness of Leukotriene Receptor Antagonists to
treat gastrointestinal symptoms during OIT (94). However, the impact on these treatments on OIT safety cannot be determined, since no RCTs have been performed.

4. Long-term safety

There is little data relating to the longer-term safety of OIT. Clearly, a major issue is that of sustained unresponsiveness vs transient desensitisation, the latter requiring ongoing regular exposure to maintain desensitisation. One concern remains issues of compliance, particularly in teenagers where this can be a problem during OIT (43). It is not uncommon for individuals who have undergone OIT to continue to experience aversion and/or oral symptoms to maintenance doses. It is not difficult to foresee a scenario where an individual is not compliant with their maintenance dosing, but believes they are now ‘tolerant’ to the allergen in question – thus risking the possibility of a severe reaction in the event of future allergen exposure.

Finally, there is also a concern that OIT can result in the development of Eosinophilic Oesophagitis (EoE) and other food-induced enteropathies. A systematic review reported EoE in up to 2.7% of patients undergoing OIT for IgE-mediated food allergy (although the review is based on incomplete datasets, since most trials of OIT have not reported the presence or absence of EoE as a longer-term adverse event) (95).

5. Conclusions

Disease-modifying treatments for food allergy are under development and have shown promising results to date, in terms of efficacy. OIT does induce desensitization, but its ability to induce permanent tolerance once ongoing exposure has stopped is limited. More research is needed into strategies – such as combining routes of exposure or identifying biomarkers of safer and successful OIT – to improve both efficacy and safety of immunotherapy treatments for food allergy (Figure 2). Safety is concerning: most patients experience reactions to OIT doses, and severe reactions have been reported. It is for this reason that the general consensus is that OIT is not ready for clinical practice (35). This will not be resolved with the current heterogeneity in reporting adverse events. Most importantly, it is time to establish an international consensus on safety data reporting from trials of immunotherapy for food allergy.
ACKNOWLEDGEMENTS

Marta Vazquez-Ortiz is supported by a Marie Skłodowska-Curie actions - Research Fellowship funded by the Commission of the European Communities (reference: 656878). Paul Turner is in receipt of a Clinician Scientist award funded by the UK Medical Research Council (reference MR/K010468/1). Both authors have received research support from the Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre awards to Imperial College London Healthcare NHS Trust.
References

1. Muraro A, Werfel T, Hoffmann-Sommergruber K, et al; EAACI Food Allergy and Anaphylaxis Guidelines Group. EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. Allergy 2014: 69: 1008-25.

2. Nwaru BI, Hickstein L, Panesar SS, et al; EAACI Food Allergy and Anaphylaxis Guidelines Group. Prevalence of common food allergies in Europe: a systematic review and meta-analysis. Allergy 2014: 69: 992-1007.

3. Branum AM, Lukacs SL. Food allergy among children in the United States. Pediatrics 2009: 124: 1549-55.

4. Turner PJ, Gowland MH, Sharma V, et al. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: An analysis of United Kingdom national anaphylaxis data, 1992-2012. J Allergy Clin Immunol 2015: 135: 956-63.

5. Prescott SL, Pawankar R, Allen KJ, et al. A global survey of changing patterns of food allergy burden in children. World Allergy Organ J 2013: 6: 21.

6. Skolnick HS, Conover-Walker MK, Koerner CB, Sampson HA, Burks W, Wood RA. The natural history of peanut allergy. J Allergy Clin Immunol 2001: 107: 367-74.

7. Begin P, Paradis L, Paradis J, et al. Natural resolution of peanut allergy: a 12-year longitudinal follow-up study. J Allergy Clin Immunol Pract 2013: 1: 528–530.

8. Wood RA, Sicherer SH, Vickery BP, et al. The natural history of milk allergy in an observational cohort. J Allergy Clin Immunol 2013: 131: 805-12.

9. Sicherer SH, Wood RA, Vickery BP, et al. The natural history of egg allergy in an observational cohort. J Allergy Clin Immunol 2014: 133: 492-9.

10. Skripak JM, Matsui EC, Mudd K, Wood RA. The natural history of IgE-mediated cow’s milk allergy. J Allergy Clin Immunol 2007: 120: 1172-7.

11. Savage JH, Matsui EC, Skripak JM, Wood RA. The natural history of egg allergy. J Allergy Clin Immunol 2007: 120: 1413-7.

12. Umasunthar T, Leonardi-Bee J, Hodes M, et al. Incidence of fatal food anaphylaxis in people with food allergy: a systematic review and meta-analysis. Clin Exp Allergy 2013: 43: 1333-41.

13. Lau GY, Patel N, Umasunthar T, et al. Anxiety and stress in mothers of food-allergic children. Pediatr Allergy Immunol 2014: 25: 236-42.

14. Cummings AJ, Knibb RC, King RM, Lucas JS. The psychosocial impact of food allergy and food hypersensitivity in children, adolescents and their families: a review. Allergy 2010: 65: 933-45.
15. Christie L, Hine RJ, Parker JG, Burks W. Food allergies in children affect nutrient intake and growth. J Am Diet Assoc 2002: 102: 1648-51.
16. Taylor SL, Hefle SL. Food allergen labeling in the USA and Europe. Curr Opin Allergy Clin Immunol 2006: 6: 186-90.
17. Fox M, Mugford M, Voordouw J, et al. Health sector costs of self-reported food allergy in Europe: a patient-based cost of illness study. Eur J Public Health 2013: 23: 757-62.
18. Boyano-Martínez T, García-Ara C, Pedrosa M, Díaz-Pena JM, Quirce S. Accidental allergic reactions in children allergic to cow's milk proteins. J Allergy Clin Immunol 2009: 123: 883-8.
19. Turner PJ, Kemp AS, Campbell DE. Advisory food labels: consumers with allergies need more than “traces” of information. BMJ 2011: 343: d6180.
20. Food Standards Agency (FSA). “May contain” labelling—the consumer’s perspective. 2002. Available at: www.food.gov.uk/multimedia/pdfs/maycontainreport.pdf
21. Noimark L, Gardner J, Warner JO. Parents’ attitudes when purchasing products for children with nut allergy: a UK perspective. Pediatr Allergy Immunol 2009: 20: 500–4.
22. Sampson MA, Muñoz-Furlong A, Sicherer SH. Risk-taking and coping strategies of adolescents and young adults with food allergy. J Allergy Clin Immunol 2006: 117: 1440-5.
23. Simons FE, Clark S, Camargo CA Jr. Anaphylaxis in the community: learning from the survivors. J Allergy Clin Immunol 2009: 124: 301–6.
24. Marrs T, Lack G. Why do few food-allergic adolescents treat anaphylaxis with adrenaline? Reviewing a pressing issue. Pediatr Allergy Immunol 2013: 24: 222-9.
25. Ford LS, Turner PJ, Campbell DE. Recommendations for the management of food allergies in a preschool/childcare setting and prevention of anaphylaxis. Expert Rev Clin Immunol 2014: 10: 867-74.
26. Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 2001: 107: 191-3
27. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. Pumphrey RS, Gowlan MD. J Allergy Clin Immunol 2007: 119: 1018-9.
28. Nurmatov, Devereux G, Worth A, Healy L, Sheikh A. Effectiveness and safety of orally administered immunotherapy for food allergies: a systematic review and meta-analysis. Br J Nutr 2014: 111: 12-22.
29. Savilahti EM, Kuitunen M, Valori M, et al. Use of IgE and IgG4 epitope binding to predict the outcome of oral immunotherapy in cow's milk allergy. Pediatr Allergy Immunol 2014: 25: 227-35.
30. Jones SM, Pons L, Roberts JL, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009: 124: 292-300.

31. Vickery BP, Scurlock AM, Jones SM, Burks AW. Mechanisms of immune tolerance relevant to food allergy. J Allergy Clin Immunol 2011: 127: 576-84.

32. Staden U, Rolinck-Werninghaus C, Brewe F, Wahn U, Niggemann B, Beyer K. Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy 2007: 62: 1261–9.

33. Burks AW, Jones SM, Wood RA, et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med 2012: 367: 233-43.

34. Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol 2014: 133: 468-75.

35. Wood RA, Sampson HA. Oral immunotherapy for the treatment of peanut allergy: is it ready for prime time? J Allergy Clin Immunol Pract 2014: 2: 97-8.

36. Brożek JL, Terracciano L, Hsu J, et al. Oral immunotherapy for IgE-mediated cow's milk allergy: a systematic review and meta-analysis. Clin Exp Allergy 2012: 42: 363-74.

37. Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgE-mediated cow’s milk allergy. Allergy 2004: 59: 980-7.

38. Garcia Rodriguez R, Urra JM, Feo-Brito F, Galindo PA, Borja J, Gomez E, et al. Oral rush desensitization to egg: efficacy and safety. Clin Exp Allergy 2011: 41: 1289–96.

39. Martorell A, De La Hoz B, Ibañez MD, et al. Oral desensitization as a useful treatment in 2-year-old children with cow’s milk allergy. Clin Exp Allergy 2011: 41: 1297-304.

40. Longo G, Barbi E, Berti I, et al. Specific oral tolerance induction in children with very severe cow’s milk-induced reactions. J Allergy Clin Immunol 2008: 121: 343-7.

41. Vazquez-Ortiz M, Alvaro-Lozano M, Alsina L, et al. Safety and predictors of adverse events during oral immunotherapy for milk allergy: severity of reaction at oral challenge, specific IgE and prick test. Clin Exp Allergy 2013: 43: 92-102.

42. Anagnostou K, Islam S, King Y, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet 2014: 383: 1297-304.

43. Vazquez-Ortiz M, Alvaro M, Piquer M, et al. Life-threatening anaphylaxis to egg and milk oral immunotherapy in asthmatic teenagers. Ann Allergy Asthma Immunol 2014: 113: 482-4.

44. Nieto A, Fernandez-Silveira L, Mazon A, Caballero L. Life-threatening asthma reaction caused by desensitization to milk. Allergy 2010: 65: 1342-3.
45. Keet CA, Seopaul S, Knorr S, Narisety S, Skripak J, Wood RA. Long-term follow-up of oral immunotherapy for cow’s milk allergy. J Allergy Clin Immunol 2013: 132: 737-9.

46. Burks AW, Wood RA, Jones SM, et al: for the Consortium of Food Allergy Research (CoFAR). Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial. J Allergy Clin Immunol 2015: 135: 1240-8.

47. Factor JM, Mendelson L, Lee J, Nouman G, Lester MR. Effect of oral immunotherapy to peanut on food-specific quality of life. Ann Allergy Asthma Immunol 2012: 109: 348-352.

48. Carraro S, Frigo AC, Perin M, et al. Impact of oral immunotherapy on quality of life in children with cow milk allergy: a pilot study. Int J Immunopathol Pharmacol 2012: 25: 793-8.

49. Otani IM, Bégin P, Kearney C, et al. Multiple-allergen oral immunotherapy improves quality of life in caregivers of food-allergic pediatric subjects. Allergy Asthma Clin Immunol 2014: 10: 25.

50. Vazquez-Ortiz M, Alvaro M, Piquet M, et al. Impact of oral immunotherapy on quality of life in eggallergic children. Pediatr Allergy Immunol 2015: 26: 291-4.

51. Savilahti EM, Kuitunen M, Valori M, et al. Use of IgE and IgG4 epitope binding to predict the outcome of oral immunotherapy in cow’s milk allergy. Pediatr Allergy Immunol 2014: 25: 227–35.

52. Otani IM, Bégin P, Kearney C, et al. Multiple-allergen oral immunotherapy improves quality of life in caregivers of food-allergic pediatric subjects. Allergy Asthma Clin Immunol 2014: 10: 25.

53. Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014: 7: 6.

54. Allam JP, Stojanovski G, Friedrichs N, et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy 2008: 63: 720–7.

55. Narisetty SD, Frischmeyer-Guerrerio PA, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol 2015: 135: 1275-82.

56. Fernández-Rivas M, Garrido-Fernández S, Nadal JA, et al. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy 2009:64:876-83.

57. Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 2005: 116: 1073-9.
58. Keet CA, Frischmeyer-Guerrero PA, Thyagarajan A, et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol 2012: 129:448-55.

59. Fleischer DM, Burks AW, Vickery BP, et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol 2013: 131:119-27.

60. Senti G, von Moos S, Küng TM. Epicutaneous Immunotherapy for Aeroallergen and Food Allergy. Curr Treat Options Allergy 2013: 1: 68-78.

61. Mondoulet L, Dioszeghy V, Larcher T, et al. Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastro-enteropathy induced by sustained oral exposure to peanuts in sensitized mice. PLoS ONE 2012: 7: e31967.

62. Dioszeghy V, Mondoulet L, Dheft V, et al. The regulatory T cells induction by epicutaneous immunotherapy is sustained and mediates long-term protection from eosinophilic disorders in peanut-sensitized mice. Clin Exp Allergy 2014: 44:867-81.

63. Dupont C, Kalach N, Soulaines P, Legoué-Morillon S, Piloquet H, Benhamou PH. Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 2010: 125: 1165-7.

64. Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of analphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 1997: 99: 744–51.

65. Nowak-Wegrzy n A, Bloom KA, Sicherer SH, et al. Tolerance to extensively heated milk in children with cow’s milk allergy. J Allergy Clin Immunol 2008: 122: 342-7.

66. Lemon-Mulé H, Sampson HA, Sicherer SH, Shreffler WG, Noone S, Nowak-Wegrzy n A. Immunologic changes in children with egg allergy ingesting extensively heated egg. J Allergy Clin Immunol 2008: 122: 977-83.

67. Turner PJ, Mehr S, Joshi P, et al. Safety of food challenges to extensively heated egg in egg-allergic children: a prospective cohort study. Pediatr Allergy Immunol 2013: 24: 450-5.

68. Martos G, Lopez-Exposito I, Bencharitiwong R, Berin MC, Nowak-Wegrzy n A. Mechanisms underlying differential food allergy response to heated egg. J Allergy Clin Immunol 2011: 127: 990–7.

69. Shin M, Lee J, Ahn K, Lee SI, Han Y. The influence of the presence of wheat flour on the antigenic activities of egg white proteins. Allergy Asthma Immunol Res 2013: 5: 42–7.

70. Kato Y, Oozawa E, Matsuda T. Decrease in antigenic and allergenic potentials of ovomucoid by heating in the presence of wheat flour: dependence on wheat variety and intermolecular disulfide bridges. J Agric Food Chem 2001: 49: 3661-5.
71. Kim JS, Nowak-Węgrzyn A, Sicherer SH, Noone S, Moshier EL, Sampson HA. Dietary baked milk accelerates the resolution of cow’s milk allergy in children. J Allergy Clin Immunol 2011: 128: 125-31.

72. Leonard SA, Sampson HA, Sicherer SH, et al. Dietary baked egg accelerates resolution of egg allergy in children. J Allergy Clin Immunol 2012: 130: 473-80.

73. Chatchatee P, Järvinen KM, Bardina L, Beyer K, Sampson HA. Identification of IgE- and IgG-binding epitopes on alpha(s1)-casein: differences in patients with persistent and transient cow’s milk allergy. J Allergy Clin Immunol 2001:107:379-83.

74. Järvinen KM, Beyer K, Vila L, Bardina L, Mishoe M, Sampson HA. Specificity of IgE antibodies to sequential epitopes of hen’s egg ovomucoid as a marker for persistence of egg allergy. Allergy 2007: 62:758-65.

75. Blanc F, Vissers YM, Adel-Patient K, et al. Boiling peanut Ara h 1 results in the formation of aggregates with reduced allergenicity. Mol Nutr Food Res 2011:55:1887-94.

76. Turner PJ, Mehr S, Sayers R et al. Loss of allergenic proteins during boiling explains tolerance to boiled peanut in peanut allergy. J Allergy Clin Immunol 2014:134:751-3.

77. Nowak-Wegrzyn A. New perspectives for use of native and engineered recombinant food proteins in treatment of food allergy. Immunol Allergy Clin North Am 2007: 27: 105-27.

78. Wood RA, Sicherer SH, Burks AW, et al. A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy. Allergy 2013: 68: 803-8.

79. Zuidmeer-Jongejan L, Fernandez-Rivas M, Poulsen LK et al. FAST: towards safe and effective subcutaneous immunotherapy of persistent life-threatening food allergies. ClinTransl Allergy 2012:2:5.

80. Couroux P, Patel D, Armstrong K, Larché M, Hafner RP. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. ClinExp Allergy 2015: 45:974-81.

81. Li S, Li XM, Burks AW, Sampson HA. Modulation of peanut allergy by peptide-based immunotherapy. J Allergy Clin Immunol 2001: 107:S233 (Abstract)

82. Prickett SR, Voskamp AL, Dacumos-Hill A, et al. Ara h 2 peptides containing dominant CD4+ T-cell epitopes: candidates for a peanut allergy therapeutic. J Allergy Clin Immunol 2011: 127: 608.

83. MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997: 158:1438-45.
84. Manohar M, Nadeau KC. The Potential of Anti-IgE in Food Allergy Therapy. Curr Treat Options Allergy 2014: 1: 145-56.

85. Leung DYM, Sampson HA, Yunginger JW, et al. Effect of Anti-IgE Therapy in Patients with Peanut Allergy. N Engl J Med 2003: 348: 986-93.

86. Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with Omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol 2011: 127: 1622-4.

87. Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol 2013: 132: 1368-74.

88. Bégin P, Dominguez T, Wilson SP et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol 2014: 10: 7.

89. Lafuente I, Mazon A, Nieto M, Uixera S, Pina R, Nieto A. Possible recurrence of symptoms after discontinuation of omalizumab in anti-IgE-assisted desensitization to egg. Pediatr Allergy Immunol. 2014: 25:717-9.

90. Fiocchi A, Burks W, Bahna SL, et al: WAO Special Committee on Food Allergy and Nutrition. Clinical Use of Probiotics in Pediatric Allergy (CUPPA): A World Allergy Organization Position Paper. World Allergy Organ J 2012: 5: 148-67.

91. Tang ML, Ponsonby AL, Orsini F et al. Administration of a probiotic with peanut oral immunotherapy: A randomized trial. J Allergy Clin Immunol 2015: 135: 737-44.

92. Frick OL, Teuber SS, Buchanan BB et al. Allergen immunotherapy with heat-killed Listeria monocytogenes alleviates peanut and food-induced anaphylaxis in dogs. Allergy 2005: 60: 243-50.

93. Skripak JM, Nash SD, Rowley H et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow’s milk allergy. J Allergy Clin Immunol 2008: 122: 1154-60.

94. Takahashi M, Taniuchi S, Soejima K, Sudo K, Hatano Y, Kaneko K. New efficacy of LTRAs (montelukast sodium): it possibly prevents food-induced abdominal symptoms during oral immunotherapy. Allergy Asthma Clin Immunol 2014: 10: 3.

95. Lucendo AJ, Arias A, Tenias JM. Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2014: 113: 624-9.
Table 1. Benefits and pitfalls of oral immunotherapy for food allergy

| Benefits                           | Pitfalls                                           |
|------------------------------------|----------------------------------------------------|
| Ability to induce desensitization  | Limited ability to induce permanent tolerance      |
| Improvement in Quality of life:     | Increased risk for allergic reactions              |
| • Dietary limitations              | Need for regular long-term consumption            |
| • Social restrictions              | Need for extensive monitoring, including long-term (resource-consuming) |
| • Emotional impact                | Failure rate: around 10-35% due to significant allergic reactions |
| • Anxiety                         | Relatively high long-term drop-out rate           |
| Improved nutrition                 |                                                    |
| Potential protection against accidental reactions |                                      |
Figure 1. Strategies under investigation to improve the efficacy and safety of OIT.

LRTA, Leukotriene receptor antagonists

Figure 2. Current knowledge gaps which need to be evaluated for their impact on safety of OIT.

SLIT, sublingual immunotherapy; EoE, Eosinophilic oesophagitis
Different routes of exposure
- Oral
- Sublingual
- Epicutaneous
- Rectal
- Subcutaneous

Hypoallergenic products
- Naturally-occurring:
  - egg/milk in baked foods
  - boiled peanut
- Recombinant
- Peptides

Adjuvants
- Anti-IgE
- Pre/probiotics
- Bacteria
- Antihistamines
- LTRA
For Peer Review

Dosing

### Updosing phase
- Can we improve **patient selection**: high risk vs low risk, risk vs benefit
- Can **adjuvants** improve safety (SLIT, anti-IgE)?
- What is the **optimal protocol** (starting dose, increase rate, duration)?

### Maintenance Phase
- Will **optimisation** of:
  - Route
  - Frequency
  - Duration
   ...improve safety?
- Can we identify **predictors** to select those who need **longer maintenance**?
- What is the role of **cofactors**?

### “Off” maintenance
- What are the **long-term health consequences**?
  - Risk of **EoE**
  - Loss of sustained tolerance +/- increased severity phenotype if tolerance lost
  - False sense of security

---

**What is the patient’s own actual** (rather than assumed) experience?

**Can we identify factors which influence compliance?** e.g. perceived burden of OIT